Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.35 |
| ▸ | DPP4 | P27487 | 3/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.31 |
| ▸ | FAP | Q12884 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8540454 | 0.72 | GSR (0.33) | GSRDPP7DPP9DPP8DPP4 | |
| SCHEMBL28305389 | 0.71 | GSR (0.61) | GSRDPP7DPP9DPP8DPP4 | |
| SCHEMBL7899765 | 0.70 | GSR (0.47) | GSRDPP7DPP9DPP8DPP4 | |
| SCHEMBL20475718 | 0.70 | GSR (0.47) | GSRDPP7DPP9DPP8DPP4 | |
| SCHEMBL7899768 | 0.70 | GSR (0.47) | GSRDPP7DPP9DPP8DPP4 | |
| SCHEMBL313305 | 0.69 | GSR (0.40) | GSRDPP7DPP9DPP8GNAI3 | |
| SCHEMBL16684 | 0.68 | GSR (0.57) | GSRDPP7DPP9DPP8DPP4 | |
| SCHEMBL20240364 | 0.68 | GSR (0.61) | GSRDPP7DPP9DPP8DPP4 | |
| SCHEMBL1404247 | 0.68 | GSR (0.61) | GSRDPP7DPP9DPP8DPP4 | |
| SCHEMBL344574 | 0.68 | GSR (0.61) | GSRDPP7DPP9DPP8DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729060-B2 | Macrocyclic polyoxazole compounds and use thereof | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-05-20 | — | — | US | disclosed |
| US-8518928-B2 | Therapeutic compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120071527-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-03-22 | — | — | US | disclosed |
| US-8093235-B2 | Macrocyclic compounds which stabilize G-Quadruplex DNA and RNA | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110230531-A1 | THERAPEUTIC COMPOUNDS | NIH - DEITR | 2011-09-22 | — | — | US | disclosed |
| EP-2183256-A1 | THERAPEUTIC COMPOUNDS | Rutgers, The State University of New Jersey (US) | 2010-05-12 | — | — | EP | disclosed |
| EP-2079704-A2 | THERAPEUTIC COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20090156627-A1 | THERAPEUTIC COMPOUNDS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-06-18 | — | — | US | disclosed |
| WO-2009018549-A1 | THERAPEUTIC COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2007127173-A2 | THERAPEUTIC COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156627-A1 | THERAPEUTIC COMPOUNDS | TOP2B, DDB1, RECQL | GSR 223/4885DPP7 4168/4885DPP9 3878/4885 |
| US-20120071527-A1 | THERAPEUTIC COMPOUNDS | TOP2B, DDB1, TOP1 | GSR 201/4885DPP7 4180/4885DPP9 3936/4885 |
| US-20110230531-A1 | THERAPEUTIC COMPOUNDS | MCL1, MKI67, NCL | GSR 280/4885DPP7 2898/4885DPP9 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.